LENZ Therapeutics Inc (NASDAQ: LENZ)’s stock price has dropped by -10.42 in relation to previous closing price of 36.95. Nevertheless, the company has seen a loss of -11.43% in its stock price over the last five trading days. zacks.com reported 2024-11-18 that After losing some value lately, a hammer chart pattern has been formed for LENZ Therapeutics, Inc. (LENZ), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Is It Worth Investing in LENZ Therapeutics Inc (NASDAQ: LENZ) Right Now?
The 36-month beta value for LENZ is at 0.62. Analysts have varying views on the stock, with 4 analysts rating it as a “buy,” 3 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for LENZ is 22.36M, and currently, shorts hold a 9.77% of that float. The average trading volume for LENZ on December 10, 2024 was 164.74K shares.
LENZ’s Market Performance
LENZ stock saw an increase of -11.43% in the past week, with a monthly gain of 1.75% and a quarterly increase of 38.26%. The volatility ratio for the week is 7.21%, and the volatility levels for the last 30 days are 7.66% for LENZ Therapeutics Inc (LENZ). The simple moving average for the last 20 days is -6.48% for LENZ’s stock, with a simple moving average of 50.75% for the last 200 days.
Analysts’ Opinion of LENZ
Many brokerage firms have already submitted their reports for LENZ stocks, with Raymond James repeating the rating for LENZ by listing it as a “Outperform.” The predicted price for LENZ in the upcoming period, according to Raymond James is $37 based on the research report published on September 27, 2024 of the current year 2024.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see LENZ reach a price target of $38. The rating they have provided for LENZ stocks is “Buy” according to the report published on August 12th, 2024.
LENZ Trading at 9.94% from the 50-Day Moving Average
After a stumble in the market that brought LENZ to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -14.98% of loss for the given period.
Volatility was left at 7.66%, however, over the last 30 days, the volatility rate increased by 7.21%, as shares sank -5.62% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +37.69% upper at present.
During the last 5 trading sessions, LENZ fell by -11.43%, which changed the moving average for the period of 200-days by +57.62% in comparison to the 20-day moving average, which settled at $35.39. In addition, LENZ Therapeutics Inc saw 166.94% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at LENZ starting from Chevallard Daniel R., who purchase 3,188 shares at the price of $15.68 back on May 14 ’24. After this action, Chevallard Daniel R. now owns 3,188 shares of LENZ Therapeutics Inc, valued at $49,988 using the latest closing price.
MCCOLLUM JAMES W, the Director of LENZ Therapeutics Inc, purchase 31,332 shares at $15.99 during a trade that took place back on May 13 ’24, which means that MCCOLLUM JAMES W is holding 525,565 shares at $501,093 based on the most recent closing price.
Stock Fundamentals for LENZ
The total capital return value is set at -0.27. Equity return is now at value -28.64, with -24.49 for asset returns.
Currently, EBITDA for the company is -122.24 million with net debt to EBITDA at 0.6. The liquidity ratio also appears to be rather interesting for investors as it stands at 28.63.
Conclusion
In conclusion, LENZ Therapeutics Inc (LENZ) has had a better performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
